Propranolol for Infants with Hemangioma: Confusion between Beta Agonists and Beta Antagonists

Roderic Phillips
Chairman of Vascular Anomalies, Royal Children's Hospital, Melbourne, Australia

*Corresponding author: Roderic Phillips, Chairman of Vascular Anomalies, Royal Children's Hospital, Melbourne, Australia, Tel: 03 9948 5005; E-mail: rod.phillips@me.com

Received date: September 12, 2016; Accepted date: October 04, 2016; Published date: October 12, 2016

Copyright: © 2016 Phillips R, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Phillips R (2016) Propranolol for Infants with Hemangioma: Confusion between Beta Agonists and Beta Antagonists Angiol 4: 185. doi:10.4172/2329-9495.1000185

Confusion between Beta Agonists and Beta Antagonists

A recent editorial [1] looked at the use of propranolol in the treatment of cosmetic infantile hemangiomas. The editorial includes the statement: "A wealth of studies in humans indicates that prenatal beta blockade induces long-term neurological complications including impaired school performance, cognitive impairment, and psychiatric disorders". This statement has alarmed some parents of infants taking propranolol. However, this statement is incorrect.

Two references for this statement are given [2,3] but neither is relevant. The paper by Feenstra [2] is about rats, not humans. The paper by Pitzer et al. [3] discusses beta-agonist use, not beta-antagonist use. It does not report any long term effects of either prenatal or postnatal beta-blockade in humans [3]. In infants treated with propranolol, the extensive anecdotal data and limited controlled study data currently available show no evidence of long term deleterious effects [4].

References